https://darkbiotechnology.com/tech-news/what-recent-point-care-molecular-diagnostics-launches-mean/ https://media.vugaenterprises.com/articles/heroes/3a259b2a5ade2d69d1f8d2860877d1b62aaae37eaaf2ef0ccf0d8a9471cf8507/1200w.webp What Recent Point-of-Care Molecular Diagnostics Launches Mean for Decentralized Testing https://darkbiotechnology.com/tech-news/all-us-release-makes-genomics-platform-largest-integrated-health/ https://media.vugaenterprises.com/articles/heroes/ac014c73913fbffcaa4585e821f187592ee0c9681b92b8545bd656f5c57936ea/1200w.webp All of Us Release Makes the Genomics Platform the Largest Integrated Health Database https://darkbiotechnology.com/tech-news/from-exascale-alphafold-computing-milestones-reshaping-biological/ https://media.vugaenterprises.com/articles/heroes/7c2f5a61b9555cf08ce0dcf2e5d106c1ce1ba22e97b29244e0c266924542f66c/1200w.webp From Exascale to AlphaFold: The Computing Milestones Reshaping Biological Research https://darkbiotechnology.com/tech-news/tandem-health-raises-100m-series-b-led-by-eqt-managed-scaleup-europe/ https://media.vugaenterprises.com/articles/heroes/3cc1c8e1cc192ae1a5c4edd993e6948eca1b1fcb1bb49d1dc71fec0cc59f213e/1200w.webp Tandem Health Raises $100M Series B Led by EQT-Managed Scaleup Europe Fund https://darkbiotechnology.com/tech-news/us-bioeconomy-policy-runs-legacy-programs-as-executive-agenda-stalls/ https://media.vugaenterprises.com/articles/heroes/f79ace09bfef391ca17b1d2cb447931a4fa151fd98e01e74bf0b301231468113/1200w.webp US Bioeconomy Policy Runs on Legacy Programs as Executive Agenda Stalls https://darkbiotechnology.com/tech-news/university-minnesota-quadruples-biomanufacturing-capability-at-new/ https://media.vugaenterprises.com/articles/heroes/b762050d8d92e69e1204acc6cfe09162794c6652bcf0e9d6ff7de4b489a0f328/1200w.webp University of Minnesota Quadruples Biomanufacturing Capability at New Facility https://darkbiotechnology.com/tech-news/pacbio-raises-vega-hifi-output-50-percent-with-sprq-nx-chemistry/ https://media.vugaenterprises.com/articles/heroes/940b254ebb89e600d817f9dd49432f8191a517e82b8c9cb4056163aba3519ec6/1200w.webp PacBio Raises Vega HiFi Output 50 Percent With SPRQ-Nx Chemistry https://darkbiotechnology.com/tech-news/sophia-genetics-astrazeneca-develop-two-precision-oncology-companion/ https://media.vugaenterprises.com/articles/heroes/5492e16678bd6cd83cb21451acec1aac5fa6d5ea99a6486534008ba89d3ad79f/1200w.webp SOPHiA GENETICS and AstraZeneca to Develop Two Precision Oncology Companion Diagnostics https://darkbiotechnology.com/tech-news/where-lab-automation-actually-stands-biotech-right-now/ https://media.vugaenterprises.com/articles/heroes/3eaef6435d34a020e9977f3251b94a1f45dea723c779bec9c08c1dbdc6182710/1200w.webp Where Lab Automation Actually Stands in Biotech Right Now https://darkbiotechnology.com/tech-news/genscript-tamarind-bio-partner-connect-ai-molecular-design-with/ https://media.vugaenterprises.com/articles/heroes/d224a1b3ac2acd24a8d8bb27a3e1f153647ff308607f2bd5b1cb59b2af8edb00/1200w.webp GenScript and Tamarind Bio Partner to Connect AI Molecular Design With Validation https://darkbiotechnology.com/biotech-news/what-biontech-s-ceo-change-signals-about-biotech-leadership-transitions/ https://media.vugaenterprises.com/articles/heroes/3ded7c63981d76a9dda0670f45c6a993d8a52f4ffd4c0acdc91b8cf3eece226e/1200w.webp What BioNTech's CEO Change Signals About Biotech Leadership Transitions https://darkbiotechnology.com/biotech-news/why-biotech-manufacturing-capacity-announcements-are-reshaping-u-s-drug/ https://media.vugaenterprises.com/articles/heroes/61a85fa9b0563ab0fb3d4cfae704ff99727001f1b27d775f3ce6d870f6c190b9/1200w.webp Why Biotech Manufacturing Capacity Announcements Are Reshaping U.S. Drug Supply https://darkbiotechnology.com/biotech-news/why-conference-abstract-is-not-publication-reading-meeting-data-with/ https://media.vugaenterprises.com/articles/heroes/2af14a59bc2d7ed7ff7bf0c86747935838f9378df1857b5ee408f9f10279d938/1200w.webp Why a Conference Abstract Is Not a Publication: Reading Meeting Data With Caution https://darkbiotechnology.com/biotech-news/halozyme-licenses-enhanze-technology-incyte-subcutaneous-inca033989-mpns/ https://media.vugaenterprises.com/articles/heroes/b25f89ef05ece5fe4776c5c605fd720faf4cb9afee8c741e1c8e371e648b9608/1200w.webp Halozyme Licenses ENHANZE Technology to Incyte for Subcutaneous INCA033989 in MPNs https://darkbiotechnology.com/biotech-news/johnson-johnson-lifts-2026-outlook-after-25-3-billion-second-quarter/ https://media.vugaenterprises.com/articles/heroes/e8c111b3af9095479efd2dfd41057ba37cff3a933c785341b48cb9b426c886d9/1200w.webp Johnson & Johnson Lifts 2026 Outlook After $25.3 Billion Second Quarter https://darkbiotechnology.com/biotech-news/fda-s-expedited-ind-comment-window-nears-close-after-gene-therapy-holds/ https://media.vugaenterprises.com/articles/heroes/d0e8f049e3fac8de404036b8285128b6d29db55173222c395a163d26b45ca094/1200w.webp FDA's Expedited IND Comment Window Nears Close After Gene Therapy Holds https://darkbiotechnology.com/biotech-news/celltrion-teva-s-truxima-becomes-first-interchangeable-rituximab/ https://media.vugaenterprises.com/articles/heroes/4a7064b7ba0f59ab640ceb18c3a5c4da753b915f9f6813eefaa9747e214a397c/1200w.webp Celltrion and Teva's Truxima Becomes First Interchangeable Rituximab Biosimilar in the US https://darkbiotechnology.com/biotech-news/gilead-lakefront-complete-1-675-billion-ouro-medicines-acquisition/ https://media.vugaenterprises.com/articles/heroes/f6fc6e56a100a91a56a0ac4a4d185b4ee610cf39c968cd3b597a43c0a9c925da/1200w.webp Gilead and Lakefront Complete $1.675 Billion Ouro Medicines Acquisition https://darkbiotechnology.com/biotech-news/parabilis-medicines-raises-record-670-million-biotech-ipo/ https://media.vugaenterprises.com/articles/heroes/cb733ccb0fa42fb30f9a0385462eaebe9cf4c18364706381356abe5e6d38a46e/1200w.webp Parabilis Medicines Raises Record $670 Million Biotech IPO https://darkbiotechnology.com/biotech-news/fda-accepts-vertex-s-povetacicept-bla-iga-nephropathy-with-november/ https://media.vugaenterprises.com/articles/heroes/b16bbf6b976fd2e4ab1e83f532b9df04eee20dd768b6cfb0c2b9b47dd0123496/1200w.webp FDA Accepts Vertex's Povetacicept BLA in IgA Nephropathy With November Decision https://darkbiotechnology.com/biotech-news/fda-approves-shionogi-s-xocova-as-first-oral-covid-19-post-exposure/ https://media.vugaenterprises.com/articles/heroes/a02aae68b1b3edda319feedd05abb2105be4e582850e070de7ce27446f6d08a6/1200w.webp FDA Approves Shionogi's Xocova as First Oral COVID-19 Post-Exposure Prophylaxis https://darkbiotechnology.com/research/how-antibiotic-resistance-research-turns-surveillance-data-into-targets/ https://media.vugaenterprises.com/articles/heroes/b918b3ceb5078a7900db50d7a527f07db4d2b6c4c203a342505942a391442c43/1200w.webp How Antibiotic Resistance Research Turns Surveillance Data Into Targets https://darkbiotechnology.com/research/how-u-s-biosecurity-policy-screens-synthetic-dna-orders/ https://media.vugaenterprises.com/articles/heroes/471158b066b66639b0ab1ce59005c1e53705aed0581f7708cb051779f0eb1474/1200w.webp How U.S. Biosecurity Policy Screens Synthetic DNA Orders https://darkbiotechnology.com/research/how-basic-research-gets-funded-grants-peer-review-payline-explained/ https://media.vugaenterprises.com/articles/heroes/f574f6c951c2395fb64f09c5958fe6f4194404b631d99b8c84cfddc69d986543/1200w.webp How Basic Research Gets Funded: Grants, Peer Review and the Payline Explained https://darkbiotechnology.com/research/why-so-many-biomedical-findings-do-not-replicate-what-journals-now/ https://media.vugaenterprises.com/articles/heroes/c153cdd862011a50d9a3b73c32f0b5bc869472114b88c108913d09cf087c4d0b/1200w.webp Why So Many Biomedical Findings Do Not Replicate — and What Journals Now Require https://darkbiotechnology.com/research/from-bench-first-human-how-drug-candidate-reaches-clinic/ https://media.vugaenterprises.com/articles/heroes/978becae708882f791dfe7a43b892f9fa06aec76d42bfb8a31c867bfc83d568b/1200w.webp From Bench to First-In-Human: How a Drug Candidate Reaches the Clinic https://darkbiotechnology.com/research/how-bioinformatics-pipelines-turn-raw-sequencing-data-into-usable/ https://media.vugaenterprises.com/articles/heroes/ea8ac61047bf58b968d14c131525325582e01394aaf49b648b42a85ed07aa912/1200w.webp How Bioinformatics Pipelines Turn Raw Sequencing Data Into Usable Biology https://darkbiotechnology.com/research/how-does-directed-evolution-engineer-proteins-industry-medicine/ https://media.vugaenterprises.com/articles/heroes/9f0aa2f3e84a9e86d43baca111f5b98f00b3c642f77fd5d3e2f0813af258cd31/1200w.webp How Does Directed Evolution Engineer Proteins for Industry and Medicine? https://darkbiotechnology.com/research/organoids-explained-what-stem-cell-models-can-cannot-do/ https://media.vugaenterprises.com/articles/heroes/e462649a605150acfe239195aa5f8af71c89c2230b849f3385f47ff443f92312/1200w.webp Organoids Explained: What Stem Cell Models Can and Cannot Do https://darkbiotechnology.com/research/how-omics-technologies-map-human-biology-at-single-cell-resolution/ https://media.vugaenterprises.com/articles/heroes/41573d8a1c0cd91701b0cdc581ebc0c0dd59ed783ed546e002d15115dc9a7d93/1200w.webp How Omics Technologies Map Human Biology at Single-Cell Resolution https://darkbiotechnology.com/research/how-early-stage-platform-science-actually-gets-validated-biotech/ https://media.vugaenterprises.com/articles/heroes/d3ec4d2609a340aba43f8a8dccbfa67b998fd1ce43380a171189822d24a31cf1/1200w.webp How Early-Stage Platform Science Actually Gets Validated in Biotech https://darkbiotechnology.com/research/ctx310-phase-1-data-published-nejm-show-single-dose-angptl3-editing/ https://media.vugaenterprises.com/articles/heroes/5f799a86b7d0f786f438c87cc1564a4dce9c85512ef8f7eae4a91ab67896355b/1200w.webp CTX310 Phase 1 Data Published in NEJM Show Single-Dose ANGPTL3 Editing Lowers Triglycerides https://darkbiotechnology.com/devices/point-care-testing-explained-clia-waivers-near-patient-diagnostics/ https://media.vugaenterprises.com/articles/heroes/3abfc2baf610e45a59bb20d958437ac98b8a94d4d979b04d4465bad826623af1/1200w.webp Point-of-Care Testing Explained: CLIA Waivers and Near-Patient Diagnostics https://darkbiotechnology.com/devices/lab-automation-devices-explained-how-total-laboratory-automation/ https://media.vugaenterprises.com/articles/heroes/11cd902edeb43a9dea36add9939cad42a6c2df81532a275f849320d5f99d7c7d/1200w.webp Lab Automation Devices Explained: How Total Laboratory Automation Reshapes Clinical Testing https://darkbiotechnology.com/devices/software-as-medical-device-explained-how-fda-regulates-standalone/ https://media.vugaenterprises.com/articles/heroes/930c21ef8963d622a236da01cfb7a0d80903dc15a8648017eb1c776ae5c84304/1200w.webp Software as a Medical Device Explained: How FDA Regulates Standalone Clinical Software https://darkbiotechnology.com/devices/how-medical-devices-get-reimbursed-medicare-coverage-pathway-explained/ https://media.vugaenterprises.com/articles/heroes/a08f232f2ab2d4524889a60974d43ce367e85dc1fc641869b60f4fc69f6d3e12/1200w.webp How Medical Devices Get Reimbursed: The Medicare Coverage Pathway Explained https://darkbiotechnology.com/devices/how-medical-device-trials-are-designed-differently-from-drug-trials/ https://media.vugaenterprises.com/articles/heroes/39d9cf608b8f515ff97c9f917188ecb94914d847d4c5e9d70b67437d9d217550/1200w.webp How Medical Device Trials Are Designed Differently From Drug Trials https://darkbiotechnology.com/devices/how-are-ai-enabled-medical-imaging-platforms-regulated-by-fda/ https://media.vugaenterprises.com/articles/heroes/a87517faae744e43e1725f682f4125c62bf9e81f60250f50909affc4130f92f6/1200w.webp How Are AI-Enabled Medical Imaging Platforms Regulated by the FDA? https://darkbiotechnology.com/devices/how-do-continuous-glucose-monitoring-devices-work-reach-market/ https://media.vugaenterprises.com/articles/heroes/33d5ff73c7857bb2e499e5af6e7b171cae38bea2ea8fc9ae2630a3f334f39b5f/1200w.webp How Do Continuous Glucose Monitoring Devices Work and Reach the Market? https://darkbiotechnology.com/devices/surgical-robotics-explained-from-puma-560-modern-operating-room/ https://media.vugaenterprises.com/articles/heroes/7cf3faec08478e43392d56e687e991a012c12c21eb06a9af86c9efa3777cc921/1200w.webp Surgical Robotics Explained: From PUMA 560 to the Modern Operating Room https://darkbiotechnology.com/devices/how-fda-regulates-wearable-health-devices-between-wellness-diagnosis/ https://media.vugaenterprises.com/articles/heroes/84698aa7f9b65d57afb1c3fcb5d7b3da512356a7fcb35a2be5c3ce5dfb0d1947/1200w.webp How FDA Regulates Wearable Health Devices Between Wellness and Diagnosis https://darkbiotechnology.com/devices/how-vitro-diagnostics-are-regulated-us-eu/ https://media.vugaenterprises.com/articles/heroes/091cbebe0175a777c4beca0e4a0dfa378ba2e47df385b442847a5565321526e8/1200w.webp How In Vitro Diagnostics Are Regulated in the US and EU https://darkbiotechnology.com/devices/fda-s-quality-management-system-regulation-takes-effect-device/ https://media.vugaenterprises.com/articles/heroes/563188ab25ec6b54968756dade0aa4966df2acac786582f0f9d29c356cbafe31/1200w.webp FDA's Quality Management System Regulation Takes Effect for Device Manufacturers https://darkbiotechnology.com/genetics/gene-synthesis-technology-explained-from-oligos-screened-genomes/ https://media.vugaenterprises.com/articles/heroes/10becef227185864feade629bb6382e1cac18de52d30d2f6a1981402a617fd7f/1200w.webp Gene Synthesis Technology Explained: From Oligos to Screened Genomes https://darkbiotechnology.com/genetics/epigenetics-platforms-explained-reading-marks-that-sit-above-genome/ https://media.vugaenterprises.com/articles/heroes/1f1ee6c4fe1d2ed6e60fe4ad449eb9246d1f9644460a4406e8202deba24f71e8/1200w.webp Epigenetics Platforms Explained: Reading the Marks That Sit Above the Genome https://darkbiotechnology.com/genetics/how-population-genomics-programs-turn-millions-genomes-into-research/ https://media.vugaenterprises.com/articles/heroes/d37e99f1c896adfdf8e333311a0dd4d3c0664eba46b7464a4e15230d0684974f/1200w.webp How Population Genomics Programs Turn Millions of Genomes Into Research Infrastructure https://darkbiotechnology.com/genetics/who-protects-your-genomic-data-gina-nih-policy-gaps/ https://media.vugaenterprises.com/articles/heroes/5a36ecb3c9d10efe22d58ad274df005d51e897651758ff3f5a521b32fb31c30f/1200w.webp Who Protects Your Genomic Data? GINA, NIH Policy and the Gaps https://darkbiotechnology.com/genetics/base-editing-prime-editing-how-crispr-moved-past-break/ https://media.vugaenterprises.com/articles/heroes/1c980a6d5155624d64064bbe3d1dcd4342ca902cd6d19d6b5b3a23b5dcb099b4/1200w.webp Base Editing and Prime Editing: How CRISPR Moved Past the Break https://darkbiotechnology.com/genetics/how-are-cell-gene-therapies-manufactured-at-commercial-scale/ https://media.vugaenterprises.com/articles/heroes/a3d72c904ec350de273ea6277eae4e27d3d4c134f92c7ed72906f64708b4a3e9/1200w.webp How Are Cell and Gene Therapies Manufactured at Commercial Scale? https://darkbiotechnology.com/genetics/how-are-gene-editing-therapies-regulated-united-states/ https://media.vugaenterprises.com/articles/heroes/9c2a50af1938b094269f3414d67ebf9bf765845561d9b13a01f91e4ddf8d8ccc/1200w.webp How Are Gene-Editing Therapies Regulated in the United States? https://darkbiotechnology.com/genetics/genetic-testing-oversight-after-ldt-rule-reversal-what-changed/ https://media.vugaenterprises.com/articles/heroes/73ef336fedd2f10332a2bf153c7c437ec9b5d4e722207bd0466da02b36e81106/1200w.webp Genetic Testing Oversight After the LDT Rule Reversal: What Changed https://darkbiotechnology.com/genetics/how-rna-therapeutics-work-how-regulators-weigh-them/ https://media.vugaenterprises.com/articles/heroes/3a9ccdc00ca852b6894783c82609555bf1cc6e9c1b4b989b5f07a33dcbe20dab/1200w.webp How RNA Therapeutics Work and How Regulators Weigh Them https://darkbiotechnology.com/genetics/geneditbio-wins-fda-ind-clearance-geb-101-tgfbi-corneal-dystrophy/ https://media.vugaenterprises.com/articles/heroes/5f77ebf9f417afa5308e3533437c8a9bb9c7cf4d385a8886c3a35c08b63ba355/1200w.webp GenEditBio Wins FDA IND Clearance for GEB-101 in TGFBI Corneal Dystrophy https://darkbiotechnology.com/genetics/vertex-presents-first-casgevy-data-children-ages-five-11-at-ash/ https://media.vugaenterprises.com/articles/heroes/76d3532c62ff555bca468a9d385d8bd97148f597c520938f5f33e25234fa98d1/1200w.webp Vertex Presents First Casgevy Data in Children Ages Five to 11 at ASH https://darkbiotechnology.com/biotech/how-biotech-earnings-season-actually-works-industry-readers/ https://media.vugaenterprises.com/articles/heroes/b988cf484b918364836de1441272d139b377f5bb7e92f711323c1dfe60b3cea0/1200w.webp How Biotech Earnings Season Actually Works for Industry Readers https://darkbiotechnology.com/biotech/cro-industry-explained-how-contract-research-organizations-run-modern/ https://media.vugaenterprises.com/articles/heroes/c73342d9a04a5a622773a9a8a77dacd2f72d0be73f097926e5ddabaad5746f69/1200w.webp The CRO Industry Explained: How Contract Research Organizations Run Modern Clinical Trials https://darkbiotechnology.com/biotech/anatomy-biotech-licensing-deal-upfronts-milestones-tiered-royalties/ https://media.vugaenterprises.com/articles/heroes/d7d53ae690f4b9a02cd61af8f610958466c9c909ee2d515a91db9cd6fcf94738/1200w.webp Anatomy of a Biotech Licensing Deal: Upfronts, Milestones and Tiered Royalties https://darkbiotechnology.com/biotech/how-orphan-drug-designation-actually-works-criteria-incentives/ https://media.vugaenterprises.com/articles/heroes/6251204576a4a895b04f55df9b88fbf8d93b118b535c2a3169c74368c41b4751/1200w.webp How Orphan Drug Designation Actually Works: Criteria, Incentives and Exclusivity https://darkbiotechnology.com/biotech/how-biomarkers-companion-diagnostics-decide-who-gets-which-therapy/ https://media.vugaenterprises.com/articles/heroes/386e001ff62e3d215f6280a12c0adf24eb5c6b8305936cc5dbc5a8b98c4b41b5/1200w.webp How Biomarkers and Companion Diagnostics Decide Who Gets Which Therapy https://darkbiotechnology.com/biotech/how-do-510-k-de-novo-pma-regulatory-pathways-compare/ https://media.vugaenterprises.com/articles/heroes/f28b3e2febf2c2473d8e86a48d1cb6befc358f69444bd59bc92539844b81e052/1200w.webp How Do 510(k), De Novo, and PMA Regulatory Pathways Compare? https://darkbiotechnology.com/biotech/biologics-manufacturing-explained-from-cell-bank-vial/ https://media.vugaenterprises.com/articles/heroes/b892bba5867a0121117c3acef3e7a8bb785182c189028a6424f19e40b6860667/1200w.webp Biologics Manufacturing Explained: From Cell Bank to Vial https://darkbiotechnology.com/biotech/how-fda-platform-technology-designation-program-actually-works/ https://media.vugaenterprises.com/articles/heroes/ed0d0e7d3ae40d02d333a61db5dbd122edd483f007c39b23125049196b9c94ce/1200w.webp How the FDA Platform Technology Designation Program Actually Works https://darkbiotechnology.com/biotech/how-biotech-financing-is-actually-structured-from-series-ipo/ https://media.vugaenterprises.com/articles/heroes/da1a302fcebdd260eca35830387c231ddf3e865d043a66b8fd24466e41c2ea37/1200w.webp How Biotech Financing Is Actually Structured, From Series A to IPO https://darkbiotechnology.com/biotech/moderna-doses-first-patient-phase-1-2-trial-mrna-2808-myeloma/ https://media.vugaenterprises.com/articles/heroes/8872f86b10cd42625cdbbde8217b40460e29bff4947ae1999061b6d330bfb883/1200w.webp Moderna Doses First Patient in Phase 1/2 Trial of mRNA-2808 in Myeloma https://darkbiotechnology.com/biotech/fda-issues-complete-response-letter-alvotech-s-golimumab-biosimilar/ https://media.vugaenterprises.com/articles/heroes/576d3becdb942a712ef5375fcf12269e6ad478aae9ed65e77f1463f774276b14/1200w.webp FDA Issues Complete Response Letter for Alvotech's Golimumab Biosimilar AVT05